Pages that link to "Q44420190"
Jump to navigation
Jump to search
The following pages link to Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation (Q44420190):
Displaying 26 items.
- Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. (Q34378623) (← links)
- T-cell therapy of leukemia. (Q34608658) (← links)
- 'GVHD': graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning (Q35122185) (← links)
- Targeting Alloreactive Donor T-Cells to Hematopoietic System-Restricted Minor Histocompatibility Antigens to Dissect Graft-versus-Leukemia Effects from Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation (Q35578576) (← links)
- Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease (Q35848361) (← links)
- Graft-versus-host disease in mini-transplant (Q35888693) (← links)
- Induction of tumor immunity following allogeneic stem cell transplantation (Q36490755) (← links)
- Cellular therapy following allogeneic stem-cell transplantation (Q36612643) (← links)
- T cell therapies following hematopoietic stem cell transplantation: surely there must be a better way than DLI? (Q36821993) (← links)
- Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant (Q36977560) (← links)
- Donor lymphocyte infusions: the long and winding road: how should it be traveled? (Q37246638) (← links)
- Targeting natural killer cells and natural killer T cells in cancer (Q37995950) (← links)
- The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond. (Q38216836) (← links)
- Strategies to accelerate immune recovery after allogeneic hematopoietic stem cell transplantation (Q38640239) (← links)
- Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation (Q38654516) (← links)
- Strategies for improving the efficacy of donor lymphocyte infusion following stem cell transplantation (Q38660984) (← links)
- Hematopoietic stem cell transplantation and cellular therapy (Q39216720) (← links)
- Non-myeloablative transplantation with CD8-depleted or unmanipulated peripheral blood stem cells: a phase II randomized trial (Q43794581) (← links)
- Retrospective comparison of CD34-selected allogeneic peripheral blood stem cell transplantation followed by CD8-depleted donor lymphocyte infusions with unmanipulated bone marrow transplantation (Q43950281) (← links)
- Donor CD4 T cells convert mixed to full donor T-cell chimerism and replenish the CD52-positive T-cell pool after alemtuzumab-based T-cell-depleted allo-transplantation (Q44300919) (← links)
- Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias (Q44319713) (← links)
- Low T-cell chimerism is not followed by graft rejection after nonmyeloablative stem cell transplantation (NMSCT) with CD34-selected PBSC (Q44603449) (← links)
- HLA class II restricted T-cell receptor gene transfer generates CD4+ T cells with helper activity as well as cytotoxic capacity (Q45885235) (← links)
- Recent publications in hematological oncology (Q74447668) (← links)
- CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study (Q80064391) (← links)
- Donor lymphocyte infusions (Q80821337) (← links)